Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Return on Sales (2023 - 2025)

Entrada Therapeutics (TRDA) has 3 years of Return on Sales data on record, last reported at 30.15% in Q4 2025.

  • For Q4 2025, Return on Sales fell 3018.0% year-over-year to 30.15%; the TTM value through Dec 2025 reached 5.65%, down 596.0%, while the annual FY2025 figure was 5.65%, 596.0% down from the prior year.
  • Return on Sales reached 30.15% in Q4 2025 per TRDA's latest filing, down from 27.31% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.81% in Q3 2023 and bottomed at 30.15% in Q4 2025.
  • Average Return on Sales over 3 years is 6.77%, with a median of 0.49% recorded in 2023.
  • Peak YoY movement for Return on Sales: skyrocketed 201bps in 2024, then crashed -3018bps in 2025.
  • A 3-year view of Return on Sales shows it stood at 0.23% in 2023, then surged by 113bps to 0.03% in 2024, then tumbled by -102154bps to 30.15% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 30.15% in Q4 2025, 27.31% in Q3 2025, and 22.12% in Q2 2025.